About Hyperion

Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology.

Hyperion aims to build its portfolio of products through partnership and in-licensing. Hyperion is currently focused on the development of one compound, glycerol phenybutyrate (HPN-100), for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). The Company acquired development rights for glyercol phenylbutyrate from Ucyclyd Pharma, Inc. (a subsidiary of Medicis Pharmaceutical Corporation) in 2007 and will obtain worldwide commercialization rights if the product is FDA-approved for UCD.

Hyperion is led by a seasoned executive team with extensive experience developing and commercializing specialty pharmaceutical products. The Company is backed by Bay City Capital, Highland Capital Partners, NEA, Panorama Capital, Sofinnova Ventures, and WRF Capital.